Stereotactic body radiotherapy vs radiofrequency ablation in the treatment of hepatocellular carcinoma: a meta-analysis

Yangxun Pan(Sun Yat-sen University), Yaojun Zhang(Sun Yat-sen University), Mian Xi(Sun Yat-sen University), Yizhen Fu(Sun Yat-sen University), Mengzhong Liu(Sun Yat-sen University), Juncheng Wang(Sun Yat-sen University), Shiliang Liu(Sun Yat-sen University), Li Xu(Fujian Medical University), Dandan Hu(Tongji University), Minshan Chen(Sun Yat-sen University), Long Qian(Anhui Medical University)
Research Square
September 19, 2019
10.21203/rs.2.14632/v1
Cited by 2

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
|Journal of Clinical Investigation|2018|190